- Home
- TRNO vs CNTA Comparison
TRNO vs CNTA Comparison
Compare TRNO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | CNTA |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.1B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRNO | CNTA |
|---|---|---|
| Price | $66.06 | $39.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $67.83 | $43.17 |
| AVG Volume (30 Days) | 460.2K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 103.65 | 29.13 |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $476,383,000.00 | $15,000,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $10.95 |
| 52 Week High | $67.55 | $40.26 |
Technical Indicators
Market Signals| Indicator | TRNO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 73.10 |
| Support Level | $59.39 | $39.16 |
| Resistance Level | $66.97 | $40.26 |
| Average True Range (ATR) | 1.67 | 0.17 |
| MACD | -0.15 | -0.44 |
| Stochastic Oscillator | 82.19 | 54.46 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.